Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.21Last Year’s EPS
-1.04Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple important positives: a commercially launched product showing early physician uptake and payer wins, strong clinical readouts and regulatory progress for late-stage programs (atumelnant and CRN09682), and a robust cash position (post-offering ~ $1.4B) with runway into 2030. Offsetting these are modest 2025 revenues relative to substantial R&D and SG&A spend, elevated 2026 operating expense guidance, and continued early-stage reimbursement and launch execution risks (≈50% Quickstart usage, uncertain conversion timings). On balance, the strengths—successful launch momentum, compelling clinical data, regulatory milestone, and a very strong balance sheet—outweigh the operational and near-term revenue challenges.Company Guidance
Successful U.S. Commercial Launch of PALSONIFY
PALSONIFY (paltusotine) launched in 2025 with Q4 net product revenue of $5.4M and total Q4 net revenue of $6.2M (including $0.8M licensing revenue from SKK). The launch generated >200 enrollment forms in Q4 and adoption by >125 unique prescribers across community and pituitary centers. Early payer momentum includes wins with top plans adding PALSONIFY to formularies with label-consistent prior authorization and no step edits.
Strong Balance Sheet and Extended Runway
Crinetics ended 2025 with >$1.0B in cash, cash equivalents and investments and, after a January 2026 public offering ($380M net proceeds), held ~ $1.4B. Management expects existing cash to fund operations into 2030, providing multi-year runway for commercialization and multiple pivotal readouts.
Promising Clinical Data for Atumelnant and Development Progress
Atumelnant (ACTH receptor antagonist) showed rapid, large biomarker responses in NIH Phase Ib/IIa ADCS data with UFC responses within days and all patients achieving serum cortisol <5 µg/dL. Global, operationally seamless Phase II/III (EQUILIBRIUM ADCS) initiated (Phase II dose range 20–80 mg/day) with Phase III powered for normalization of 24-hour urine-free cortisol; open-label extension included.
Pipeline Expansion: CRN09682 Phase I/II Initiation
First candidate from non-peptide drug conjugate program (CRN09682) entered dose escalation in a Phase I/II basket trial (BRAVESST) targeting SST2-expressing tumors. Broad tumor eligibility (NETs, meningioma, others) with clear PET-based SST2 selection criteria and encouraging preclinical signals (including small cell lung carcinoma models).
Regulatory Progress in Europe
Received a positive CHMP opinion for PALSONIFY in the EU for acromegaly, representing an important regulatory milestone supporting global commercialization plans.
Disciplined 2025 Cash Usage vs Guidance
Used $326.2M of total net cash in 2025, favorable to guidance of $340M–$370M (management attributed the variance to working capital timing and higher employee option proceeds), demonstrating execution in line with financial planning.
CRNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $43.74 | $41.10 | -6.04% |
Nov 06, 2025 | $43.49 | $40.00 | -8.02% |
Aug 07, 2025 | $27.88 | $26.85 | -3.69% |
May 08, 2025 | $32.70 | $30.68 | -6.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Crinetics Pharmaceuticals (CRNX) report earnings?
Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Crinetics Pharmaceuticals (CRNX) earnings time?
Crinetics Pharmaceuticals (CRNX) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRNX EPS forecast?
CRNX EPS forecast for the fiscal quarter 2026 (Q1) is -1.21.